SCHEMBL6497264

SCHEMBL6497264

COc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)cc2c1OCCO2

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.53
BCR P11274 2/20 0.53
PRKCA P17252 1/20 0.53
PRKCD Q05655 1/20 0.53
CAMK2D Q13557 6/20 0.52
CDK2 P24941 3/20 0.52
CDK1 P06493 1/20 0.52
SMG1 Q96Q15 1/20 0.52
MAPT P10636 1/20 0.48
PIK3CG P48736 6/20 0.48
PIK3CA P42336 5/20 0.48
PIK3CB P42338 5/20 0.48
JAK2 O60674 2/20 0.48
EGFR P00533 1/20 0.48
PTK2B Q14289 1/20 0.48
PLK1 P53350 1/20 0.47
FLT3 P36888 1/20 0.47
CDK4 P11802 1/20 0.47
CSNK2A1 P68400 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12764224 0.82 ABL1 (0.62) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL8254301 0.82 PIK3CG (0.69) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL14040916 0.81 CLK1 (0.53) ABL1PRKCAPRKCDCDK2SMG1
SCHEMBL4712159 0.76 SMG1 (0.57) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL12800918 0.76 CAMK2D (0.67) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL5733563 0.75 MAPT (0.72) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL27116597 0.75 PIK3CG (0.73) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL12275494 0.74 PLK1 (0.70) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL12274914 0.73 CAMK2D (0.57) ABL1BCRPRKCAPRKCDCAMK2D
SCHEMBL3614861 0.73 ABL1 (0.61) ABL1BCRPRKCAPRKCDCAMK2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949544-B2 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-09-27 US disclosed
US-20030087922-A1 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087922-A1 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases CDK2, LCK, CDK5 ABL1 255/4885BCR 1092/4885PRKCA 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.